Sunday, January 17, 2021
Home News Reports Glenmark starts phase-3 clinical trial for potential coronavirus drug ‘Favipiravir’ in India

Glenmark starts phase-3 clinical trial for potential coronavirus drug ‘Favipiravir’ in India

Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses, like the Novel Coronavirus

On Tuesday, Glenmark Pharmaceuticals said that it has initiated Phase-3 clinical trials of antiviral tablet Favipiravir, a potential drug for the Coronavirus after it received approval from the country’s drug regulator last month.

According to the reports, Glenmark is the first company in India to initiate Phase-3 clinical trials on Favipiravir for coronavirus patients in the country. Favipiravir is manufactured under the brand name Avigan by Fujifilm Toyama Chemical Co Ltd, a subsidiary of Japan’s Fujifilm Holdings Corporation. It was approved for use as an anti-flu drug in the country in 2014.

The drug company said that they have already started the clinical trials and more than 10 leading government and private hospitals in India are being enrolled for the study. It estimates the study completion by July or August this year.

Favipiravir is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses, like the Novel Coronavirus. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs.

It may be noted that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.

To be commercialised under the name ‘FabiFlu’

The company said it has successfully developed API and the formulations for the product through its in house research and development team. The molecule will be marketed under the brand name ‘FabiFlu’ if commercialised in India.

Dr Monika Tandon, vice president and head of clinical development said, “Several health and medical experts, both in and outside of Glenmark, are eager to see the effect that Favipiravir has on COVID-19 cases. We believe the study results will be significant as there is currently no effective treatment for the virus”.

She added that the data they get from these trials will point us in a clearer direction with regard to coronavirus treatment and management.

“We believe the study results will be significant as there is currently no effective treatment for the virus. The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management,” Tandon said.

As per the approved clinical trial protocol, 150 subjects with mild to moderate coronavirus will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care. The duration of the treatment is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.

  Support Us  

Whether NDTV or 'The Wire', they never have to worry about funds. In name of saving democracy, they get money from various sources. We need your support to fight them. Please contribute whatever you can afford

OpIndia Staffhttps://www.opindia.com
Staff reporter at OpIndia

Related Articles

Trending now

US State Department releases fact sheet alleging Covid-19 virus may have originated in Wuhan Institute of Virology, demands a thorough probe

US state department says that Wuhan Institute of Virology was studying the bat virus, and several researches had become sick

Nidhi Razdan, fake Harvard professorship and her blog explaining the fiasco, which raises more questions than answers: Details

Nidhi Razdan has now penned a blog detailing how she fell victim to a phishing attack promising her professorship at Harvard.

“Absolutely rubbish”, “Propaganda driven” and “Hinduphobic”: Netizens call for a boycott of Tandav web-series on Amazon Prime

Saif Ali Khan-starrer Tandav on Amazon Prime is drawing severe flak online for its Hinduphobic content

What the Nidhi-Harvard story reveals about our world: Get off your high horse, you are not that special, anyway

Liberal journalist, Nidhi Razdan, thought she had received an offer from Harvard University to become an Associate Professor of journalism.

They’re paying someone in Taloja to torture him till he names Arnab, he’s on death bed: Ex-BARC CEO family speak up, file affidavit

Days after they arrested BARC COO Romil Ramgarhia, they arrested BARC former CEO Partho Dasgupta on the 25th of December 2020.

Anti-farm law protesters attack vaccination center in Haryana, chase doctors away: Details

Chaotic scenes were observed in Kaithal, Haryana where an attempt was made to chase doctors away from the vaccination center.

Recently Popular

Nidhi Razdan was scammed into believing she got an offer from the real Harvard University to become a professor of journalism: Details

Nidhi Razdan, formerly with NDTV, has revealed that she was the victim of a phishing attack and Harvard never came calling.

The Nidhi Razdan Harvard fiasco: A user had sounded off the alarms as early as September 2020

Nidhi Razdan revealed on Friday that she fell victim to a phishing scam and confirmed that she was never offered a job by Harvard.

Ravish Kumar apologises for spreading fake news about paddy procurement by govt after letter to NDTV by PIB: Here is what he said

After getting caught for peddling fake news about paddy procurement by govt, controversial NDTV news anchor Ravish Kumar has apologized

All you need to know about Jhanvi Kukreja murder case, the teenage girl who was brutally killed at a New Year party in Mumbai

Reports suggest that the injuries incurred by Jhanvi Kukreja were homicidal and not accidental

‘Tit for Tat’, ‘Work of Art’: Netizens react to the Nidhi Razdan Harvard fiasco, question her logic

Netizens have been commenting on the Nidhi Razdan Harvard fiasco and pointed out the incredulousness of the whole situation.

Vanishing barons: Alibaba founder Jack Ma and 4 other Chinese billionaires who had mysteriously gone missing

Several prominent elites from China who had ran afoul with the CCP had mysteriously disappeared from the public eye, including Jack Ma

US State Department releases fact sheet alleging Covid-19 virus may have originated in Wuhan Institute of Virology, demands a thorough probe

US state department says that Wuhan Institute of Virology was studying the bat virus, and several researches had become sick

How luck favoured ‘yorker specialist’ Natarajan and he became a game-changer for the Indian cricket team in Australia

While Indian fans await his splendid performance in the second innings of the Brisbane Test, for T Natarajan, the game has just begun.

On Day 1 of the COVID-19 vaccination drive, 1.65 lakh beneficiaries vaccinated across 3,351 sites in India

PM Modi launched the world's biggest COVID-19 vaccination drive in the country today at 10:30 am via video conferencing

Nidhi Razdan, fake Harvard professorship and her blog explaining the fiasco, which raises more questions than answers: Details

Nidhi Razdan has now penned a blog detailing how she fell victim to a phishing attack promising her professorship at Harvard.

‘Temple attacks in Andhra have enraged Hindu community, state govt not taking any action,’ Pejavara Mutt’s seer writes to Amit Shah

The seer has sought a committee of intelligence officials to conduct a transparent inquiry on the temple attacks in Andhra

“Absolutely rubbish”, “Propaganda driven” and “Hinduphobic”: Netizens call for a boycott of Tandav web-series on Amazon Prime

Saif Ali Khan-starrer Tandav on Amazon Prime is drawing severe flak online for its Hinduphobic content

What the Nidhi-Harvard story reveals about our world: Get off your high horse, you are not that special, anyway

Liberal journalist, Nidhi Razdan, thought she had received an offer from Harvard University to become an Associate Professor of journalism.

Kerala state board Class 9 textbook distorts history, claims Abu al-Qasim Al-Zahwari was the ‘Father of Surgery’ instead of Sushrutha

Indian physician Sushrutha, who lived much earlier than Al-Zahwari, is considered to be the 'father of surgery'

They’re paying someone in Taloja to torture him till he names Arnab, he’s on death bed: Ex-BARC CEO family speak up, file affidavit

Days after they arrested BARC COO Romil Ramgarhia, they arrested BARC former CEO Partho Dasgupta on the 25th of December 2020.

Connect with us

245,563FansLike
496,912FollowersFollow
22,700SubscribersSubscribe